Estimates of HIV incidence among persons testing for HIV using the sensitive/less sensitive enzyme immunoassy, New York City, 2001

Journal of Acquired Immune Deficiency Syndromes

Volumn 39, Issue 1, 2005, Pages 102-111

  Nash, Denis ^a,b   Bennani, Yussef ^a   Ramaswamy, Chitra ^a   Torian, Lucia ^a  

^a Bureau of HIV/AIDS Prevention and Control   (United States)

^b NEW YORK ACADEMY OF MEDICINE   (United States)

Author keywords

HIV; HIV incidence; Less sensitive enzyme immunoassay; STARHS; Surveillance

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEALTH SURVEY; HETEROSEXUALITY; HIGH RISK POPULATION; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INCIDENCE; INFECTION RISK; INTRAVENOUS DRUG ABUSE; LESS SENSITIVE ENZYME IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; SEX RATIO; UNITED STATES; VIRUS TRANSMISSION; WESTERN BLOTTING;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AGE OF ONSET; DEMOGRAPHY; FEMALE; HIV INFECTIONS; HIV SEROPOSITIVITY; HOMOSEXUALITY, MALE; HUMANS; IMMUNOENZYME TECHNIQUES; INCIDENCE; MALE; MIDDLE AGED; NEW YORK CITY; PRISONERS; RISK FACTORS; RISK-TAKING; SENSITIVITY AND SPECIFICITY; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 18144389404     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000144446.52141.4c     Document Type: Article

References (29)

1. Guidelines for evaluating surveillance systems. MMWR Morb Mortal Wkly Rep. 1988;37(Suppl 5):1-18.
2. Guidelines for national human immunodeficiency virus case surveillance, including monitoring for human immunodeficiency virus infection and acquired immunodeficiency syndrome. Centers for Disease Control and Prevention. MMWR Recomm Rep. 1999;48(RR-13):1-27, 29-31.
3. Diagnosis and reporting of HIV and AIDS in states with HIV/AIDS surveillance: United States, 1994-2000. MMWR Morb Mortal Wkly Rep. 2002;51:595-598.
4. Diagnosis and reporting of HIV and AIDS in states with integrated HIV and AIDS surveillance: United States. January 1994-June 1997. MMWR Morb Mortal Wkly Rep. 1998;47:309-314.
5. Alcabes P, Munoz A, Vlahov D, et al. Incubation period of human immunodeficiency virus. Epidemiol Rev. 1993;15:303-318.
6. Weinstock H, Dale M, Gwinn M, et al. HIV seroincidence among patients at clinics for sexually transmitted diseases in nine cities in the United States. J Acquir Immune Defic Syndr. 2002;29:478-483.
7. Schwarcz S, Kellogg T, McFarland W, et al. Differences in the temporal trends of HIV seroincidence and seroprevalence among sexually transmitted disease clinic patients, 1989-1998: application of the serologic testing algorithm for recent HIV seroconversion. Am J Epidemiol. 2001;153:925-934.
8. Schwarcz SK, Kellogg TA, McFarland W, et al. Characterization of sexually transmitted disease clinic patients with recent human immunodeficiency virus infection. J Infect Dis. 2002;186:1019-1022.
9. McFarland W, Busch MP, Kellogg TA, et al. Detection of early HIV infection and estimation of incidence using a sensitive/less-sensitive enzyme immunoassay testing strategy at anonymous counseling and testing sites in San Francisco. J Acquir Immune Defic Syndr. 1999;22:484-489.
10. McFarland W, Kellogg TA, Dilley J, et al. Estimation of human immunodeficiency virus (HIV) seroincidence among repeat anonymous testers in San Francisco. Am J Epidemiol. 1997;146:662-664.
11. McFarland W, Kellogg TA, Louie B, et al. Low estimates of HIV seroconversions among clients of a drug treatment clinic in San Francisco, 1995 to 1998. J Acquir Immune Defic Syndr. 2000;23:426-429.
12. Kellogg T, McFarland W, Katz M. Recent increases in HIV seroconversion among repeat anonymous testers in San Francisco, AIDS. 1999;13:2303-2304.
13. Kellogg TA, Clements-Nolle K, Dilley J, et al. Incidence of human immunodeficiency virus among male-to-female transgendered persons in San Francisco. J Acquir Immune Defic Syndr. 2001;28:380-384.
14. Kellogg TA, McFarland W, Perlman JL, et al. HIV incidence among repeat HIV testers at a county hospital, San Francisco, California, USA. J Acquir Immune Defic Syndr. 2001;28:59-64.
15. HIV incidence among young men who have sex with men: seven U.S. cities, 1994-2000. MMWR Morb Mortal Wkly Rep. 2001;50:440-444.
16. Janssen RS, Satten GA, Stramer SL, et al. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA. 1998;280:42-48.
17. Kothe D, Byers RH, Caudill SP, et al. Performance characteristics of a new less sensitive HIV-1 enzyme immunoassay for use in estimating HIV seroincidence. J Acquir Immune Defic Syndr. 2003;33:625-634.
18. Lee LM, McKenna MT, Janssen RS. Classification of transmission risk in the national HIV/AIDS surveillance system. Public Health Rep. 2003;118:400-407.
19. CDC. HIV/AIDS Surveillance Report. Vol. 13, no. 2. Atlanta: Centers for Disease Control and Prevention; 2001.
20. Schmidt MA, Mokotoff ED. HIV/AIDS surveillance and prevention: improving the characterization of HIV transmission. Public Health Rep. 2003;118:197-204.
21. Hajat A, Nash D, Schillinger JA, et al. NYC Vital Signs: Sex in the City: More HIV Testing and Condom Use Needed! New York, NY: New York City Department of Health and Mental Hygiene; 2003.
22. ASHA. Sexually Transmitted Diseases in America: How Many Cases and at What Cost?: Kaiser Family Foundation; Menlo Park, CA; 1998.
23. Erickson PI, Bastani R, Maxwell AE, et al. Prevalence of anal sex among heterosexuals in California and its relationship to other AIDS risk behaviors. AIDS Educ Prev. 1995;7:477-493.
24. Seroprevalence Update HIV. New York City Department of Health; 1999.
25. MacKellar DA, Valleroy LA, Secura GM, et al. Repeat HIV testing, risk behaviors, and HIV seroconversion among young men who have sex with men: a call to monitor and improve the practice of prevention. J Acquir Immune Defic Syndr. 2002;29:76-85.
26. Des Jarlais DC, Marmor M, Friedmann P, et al. HIV incidence among injection drug users in New York City, 1992-1997: evidence for a declining epidemic. Am J Public Health. 2000;90:352-359.
27. Des Jarlais C, Perlis T, Friedman SR, et al. Behavioral risk reduction in a declining HIV epidemic: injection drug users in New York City, 1990-1997. Am J Public Health. 2000;90:1112-1116.
28. Primary and secondary syphilis among men who have sex with men: New York City, 2001. MMWR. 2002;51:853-856.
29. Nash D, Ramaswamy C, Manning SE. Implementation of named HIV reporting. New York City, 2001. MMWR Morb Mortal Wkly Rep. 2004;52:1248-1252.